1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Mental Health Industry Analysis, August 2019

Mental Health Industry Analysis, August 2019

1-30 of 38 reports

Tropifexor

Tropifexor

  • $ 10000
  • Industry report
  • July 2019

FXR is a nuclear receptor that regulates bile acid metabolism and signaling. Activation of the receptor inhibits bile acid synthesis from cholesterol via cytochrome P450 7A1 and increases bile acid conjugation, ...

  • Industries : Mental Health, Pathology
Fetzima

Fetzima

  • $ 10000
  • Industry report
  • March 2019

Fetzima (levomilnacipran; Allergan) is a serotonin-norepinephrine reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in the US.

  • Industries : Mental Health, Therapy, Pathology
  • Countries : United States
Cymbalta

Cymbalta

  • $ 10000
  • Industry report
  • March 2019

Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since ...

  • Industries : Pathology, Chronic Disease, Therapy, Mental Health
  • Countries : United States, Japan, European Union
Abilify/Abilify Maintena, Pharma Intelligence

Abilify/Abilify Maintena, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Latuda

Latuda

  • $ 10000
  • Industry report
  • March 2019

Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the ...

  • Industries : Mental Health, Pathology
  • Countries : Japan, United States, Germany, Italy, Spain, United Kingdom
Seroquel/Seroquel XR, Pharma Intelligence

Seroquel/Seroquel XR, Pharma Intelligence

  • $ 10000
  • Industry report
  • March 2019

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
SAGE-217

SAGE-217

  • $ 10000
  • Industry report
  • March 2019

SAGE-217 (oral brexanolone; SAGE Therapeutics/Shionogi) is a novel, next-generation positive allosteric modulator that selectively binds synaptic and extrasynaptic gamma-aminobutyric acid-A (GABA-A) receptors ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Trintellix

Trintellix

  • $ 10000
  • Industry report
  • March 2019

Trintellix (vortioxetine; Lundbeck/Takeda) is the latest antidepressant to be approved in the US for major depressive disorder (MDD). The drug follows a successful line of antidepressants developed by ...

  • Industries : Mental Health, Therapy, Pathology
  • Countries : United States
Rexulti

Rexulti

  • $ 10000
  • Industry report
  • March 2019

Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Market Spotlight: Eating Disorders, Pharma Intelligence

Market Spotlight: Eating Disorders, Pharma Intelligence

  • $ 1318
  • Industry report
  • March 2019

This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, ...

  • Industries : Mental Health, Pathology
  • Countries : World
Alzheimer’s Disease Market and Forecast Analysis 2034

Alzheimer’s Disease Market and Forecast Analysis 2034

  • $ 22000
  • Industry report
  • February 2019

Disease OverviewAlzheimer’s disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function. Alzheimer’s disease is the most common ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Epilepsy KOL Interview – US, West

Epilepsy KOL Interview – US, West

  • $ 599
  • Industry report
  • February 2019

OverviewA US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Pediatric Epilepsy KOL Interview – US, West

Pediatric Epilepsy KOL Interview – US, West

  • $ 599
  • Industry report
  • February 2019

OverviewA US expert in pediatric epilepsy provides insight into the approach to treating different forms of epilepsy. The key opinion leader (KOL) dives into the late-phase pipeline for epilepsy, as well ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?, Pharma Intelligence

Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?, Pharma Intelligence

  • $ 1318
  • Industry report
  • February 2019

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD)? market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming ...

  • Industries : Mental Health, Pathology
  • Countries : World
Market Spotlight: Amyotrophic Lateral Sclerosis (ALS), Pharma Intelligence

Market Spotlight: Amyotrophic Lateral Sclerosis (ALS), Pharma Intelligence

  • $ 1318
  • Industry report
  • January 2019

This Market Spotlight report covers the Amyotrophic Lateral Sclerosis (ALS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-yea ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Alzheimer’s Disease KOL Interview – UK

Alzheimer’s Disease KOL Interview – UK

  • $ 599
  • Industry report
  • January 2019

OverviewThis interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in ...

  • Industries : Mental Health, Pathology
  • Countries : United Kingdom
Alzheimer’s Disease KOL Interview – US, South

Alzheimer’s Disease KOL Interview – US, South

  • $ 599
  • Industry report
  • January 2019

OverviewThis interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. ...

  • Industries : Mental Health
  • Countries : United States
Alzheimer’s Disease KOL Interview – US, Northeast

Alzheimer’s Disease KOL Interview – US, Northeast

  • $ 599
  • Industry report
  • January 2019

OverviewThis interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. ...

  • Industries : Mental Health
  • Countries : United States
Major Depressive Disorder KOL Interview – UK

Major Depressive Disorder KOL Interview – UK

  • $ 599
  • Industry report
  • December 2018

OverviewA UK key opinion leader (KOL) provides insight into the critical unmet needs in the depression market, along with future trends. Key late-phase pipeline drugs for major depressive disorder and ...

  • Industries : Mental Health, Pathology
  • Countries : United Kingdom
Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Embolization Systems

Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Embolization Systems

  • $ 4750
  • Industry report
  • November 2018

OverviewThis medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and arteriovenous malformation (AVM) embolization systems. ...

  • Industries : Mental Health, Pathology
Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

  • $ 599
  • Industry report
  • October 2018

OverviewA US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1

Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1

  • $ 599
  • Industry report
  • October 2018

OverviewA US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.

  • Industries : Mental Health, Pathology
  • Countries : United States
Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

  • $ 4750
  • Industry report
  • August 2018

OVERVIEWThis analysis includes a discussion of Deep Brain Stimulation (DBS) and Vagus Nerve Stimulation (VNS) devices, technological innovations, competitors, trends, and expected market growth. Market ...

  • Industries : Mental Health, Pathology
  • Countries : United States, World
Epilepsy Forecast and Market Analysis to 2035

Epilepsy Forecast and Market Analysis to 2035

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWEpilepsy is characterized by recurrent, unprovoked seizures. A seizure occurs when the normal pattern of neuronal activity is disturbed, defined by the National Institute of Neurological ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Multiple Sclerosis Forecast and Market Analysis to 2025, Pharma Intelligence

Multiple Sclerosis Forecast and Market Analysis to 2025, Pharma Intelligence

  • $ 22000
  • Industry report
  • July 2018

DISEASE OVERVIEWMultiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Parkinson’s disease forecast and market analysis to 2035

Parkinson’s disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • June 2018

Disease OverviewParkinson’s disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Gocovri

Gocovri

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewGocovri (Adamas Pharmaceuticals) is an extended-release formulation of amantadine, uniquely indicated for the treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease. While ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Xadago

Xadago

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewXadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible ...

  • Industries : Mental Health, Pathology
  • Countries : United States
Duopa

Duopa

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewAbbVie’s Duopa, a continuous intestinal infusion of a carbidopa plus levodopa gel, is indicated for the treatment of advanced-stage idiopathic Parkinson’s disease with motor fluctuations ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
ND0612

ND0612

  • $ 10000
  • Industry report
  • June 2018

Drug OverviewThe ND0612 (Mitsubishi Tanabe) product line comprises two subcutaneous, continuously delivered carbidopa/levodopa liquid formulations: the lower-dose ND0612L, and the higher-dose ND0612H. ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on